SW
NBIX icon

SkyOak Wealth’s Neurocrine Biosciences NBIX Stock Holding History

SkyOak Wealth’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2,000
Closed -$244K – 228
2020
Q2 		$244K Buy
+2,000
New +$221K 0.09% 202
2020
Q1 		– Sell
-2,448
Closed -$263K – 264
2019
Q4 		$263K Buy
+2,448
New +$256K 0.08% 249

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SkyOak Wealth's NBIX Position: Q3 2020 in Review

SkyOak Wealth sold out of Neurocrine Biosciences (NBIX) in Q3 2020, closing a stake of 2,000 shares — an estimated $244K sold.

SkyOak Wealth first reported a position in NBIX in Q4 2019 and held it in 2 quarters. The position peaked at $263K in Q4 2019. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • SkyOak Wealth reported no remaining Neurocrine Biosciences position as of Q3 2020 after selling out during the quarter.
  • SkyOak Wealth sold 2,000 Neurocrine Biosciences shares in Q3 2020, an estimated $244K.
  • SkyOak Wealth first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 2 quarters.
  • SkyOak Wealth's Neurocrine Biosciences position peaked at $263K in Q4 2019.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on SkyOak Wealth's 13F filing for Q3 2020, filed 3 Nov 2020.